221 related articles for article (PubMed ID: 35305097)
1. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
2. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
6. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
7. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
[TBL] [Abstract][Full Text] [Related]
9. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
10. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
12. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
13. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Ludmir EB; Kachnic LA; Czito BG
Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
[TBL] [Abstract][Full Text] [Related]
16. Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903).
Ito Y; Hamaguchi T; Takashima A; Mizusawa J; Shimada Y; Shiozawa M; Mizoguchi N; Kodaira T; Komori K; Ohue M; Konishi K; Teraishi F; Kinouchi M; Murata K; Fujita F; Watanabe M; Iinuma G; Ishida F; Saida Y; Matsuda T; Katayama H; Fukuda H; Kanemitsu Y;
Int J Clin Oncol; 2023 Aug; 28(8):1063-1072. PubMed ID: 37286878
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma.
Li J; Huang C; Wang X; Li Z; Shen Y
Clin Transl Oncol; 2024 Mar; 26(3):739-746. PubMed ID: 37568008
[TBL] [Abstract][Full Text] [Related]
19. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.
Koerber SA; Slynko A; Haefner MF; Krug D; Schoneweg C; Kessel K; Kopp-Schneider A; Herfarth K; Debus J; Sterzing F
Radiat Oncol; 2014 May; 9():113. PubMed ID: 24886574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
